Stoke Therapeutics Inc
STOK
NASDAQ
Biotechnology
$31.27
USD
-0.04 (-0.13%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.04B
Volume 495.1K
Revenue
$27.59M
TTM
-86.2%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-146.28M
TTM
-292.6%
YoY
Operating Cash Flow
$-121.40M
TTM
-239.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 13.8 | 10.6 | 1.4 | 6.2 | 9.3 |
YoY Growth | +186.0% | +117.2% | -93.8% | -96.1% | -32.5% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 13.8 | 10.6 | 1.4 | 6.2 | 9.3 |
Selling, General & Administrative | 15.3 | 16.0 | 21.1 | 20.0 | 25.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 41.1 | 53.7 | 62.8 | 59.6 | 74.8 |
Operating Income | -27.3 | -43.1 | -61.4 | -53.4 | -65.4 |
EBITDA | -27.3 | -42.6 | -61.0 | -53.0 | -65.4 |
Other Income / Expense | 0.0 | 0.0 | -0.1 | 0.0 | 0.3 |
Total Other Income / Expense | 3.8 | 3.5 | 3.5 | 3.4 | 3.8 |
Income Before Income Taxes | -23.5 | -39.6 | -57.9 | -50.0 | -61.6 |
Income Taxes | 0.0 | -1.3 | 0.0 | 0.0 | 0.0 |
Net Income | 0.0 | -38.3 | -57.9 | -50.0 | 0.0 |
Consolidated Net Income / Loss | -23.5 | -38.3 | -57.9 | -50.0 | -61.6 |
Net Income Attributable to Common Shareholders | -23.5 | -38.3 | -57.9 | -50.0 | -61.6 |
Basic EPS | -$0.40 | -$0.65 | -$0.93 | -$0.79 | -$0.93 |
Diluted EPS | -$0.40 | -$0.65 | -$0.96 | -$0.79 | -$0.93 |
Basic Shares Outstanding | 58.4M | 58.6M | 62.0M | 63.1M | 66.0M |
Diluted Shares Outstanding | 58.4M | 58.6M | 60.5M | 63.1M | 66.0M |